Comments on: (Dapagliflozin + zibotentan) by AstraZeneca for Chronic Kidney Disease (Chronic Renal Failure): Likelihood of Approval /data-insights/dapagliflozin-zibotentan-astrazeneca-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ The leading site for news and procurement in the pharmaceutical industry Thu, 04 Jul 2024 23:16:21 +0000 hourly 1 https://wordpress.org/?v=6.6.2